Arcoma

Arcoma Equity Growth

The Year-over-Year Equity Growth of Arcoma (ARCOMA.ST) as of Nov 3, 2026 is 25.94 %. In the previous year, Year-over-Year Equity Growth was 21.94 % — a change of 18.23% (higher).

Equity Growth

25.94 %

YoY

18.23%

Last updated:

Year-over-Year Equity Growth of Arcoma is 2025 25.94 % . Year-over-Year Equity Growth of Arcoma was 2024 21.94 % . It decreases by 18.23% higher compared to the previous year.

The Arcoma Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
-4.41 SEK
Jan 1, 2019
15.76 SEK
Jan 1, 2020
9.62 SEK
Jan 1, 2021
-11.09 SEK
Jan 1, 2022
4.17 SEK
Jan 1, 2023
6.06 SEK
Jan 1, 2024
21.94 SEK
Jan 1, 2025
25.94 SEK
The Arcoma Equity Growth history
YEAREquity GrowthYoY
25.94 %+18.23%
21.94 %+261.85%
6.06 %+45.38%
4.17 %-137.61%
-11.09 %-215.33%
9.62 %-38.99%
15.76 %-457.54%
-4.41 %-147.23%
9.33 %-137.07%
-25.18 %-228.31%
19.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Year-over-Year Equity Growth of Arcoma is 25.94 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Arcoma since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Arcoma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Arcoma

All Key Metrics — Arcoma